UCSF Diabetes Center, UCSF, San Francisco, California, USA.
Department of Biochemistry, University of Wisconsin-Madison, DeLuca Biochemistry Laboratories, Madison, Wisconsin, USA.
JCI Insight. 2023 Jun 8;8(11):e157572. doi: 10.1172/jci.insight.157572.
Insulin secretion from pancreatic β cells is essential to the maintenance of glucose homeostasis. Defects in this process result in diabetes. Identifying genetic regulators that impair insulin secretion is crucial for the identification of novel therapeutic targets. Here, we show that reduction of ZNF148 in human islets, and its deletion in stem cell-derived β cells (SC-β cells), enhances insulin secretion. Transcriptomics of ZNF148-deficient SC-β cells identifies increased expression of annexin and S100 genes whose proteins form tetrameric complexes involved in regulation of insulin vesicle trafficking and exocytosis. ZNF148 in SC-β cells prevents translocation of annexin A2 from the nucleus to its functional place at the cell membrane via direct repression of S100A16 expression. These findings point to ZNF148 as a regulator of annexin-S100 complexes in human β cells and suggest that suppression of ZNF148 may provide a novel therapeutic strategy to enhance insulin secretion.
胰岛β细胞的胰岛素分泌对于维持葡萄糖内环境稳定至关重要。该过程的缺陷会导致糖尿病。鉴定出影响胰岛素分泌的遗传调控因子对于确定新的治疗靶点至关重要。在这里,我们发现 ZNF148 在人胰岛中的减少及其在干细胞衍生的β细胞(SC-β细胞)中的缺失会增强胰岛素分泌。ZNF148 缺陷的 SC-β细胞的转录组学鉴定出 Annexin 和 S100 基因的表达增加,其蛋白质形成参与调节胰岛素囊泡运输和胞吐的四聚体复合物。SC-β 细胞中的 ZNF148 通过直接抑制 S100A16 的表达来阻止 Annexin A2 从细胞核易位到其在细胞膜上的功能位置。这些发现表明 ZNF148 是人类β细胞中 Annexin-S100 复合物的调节剂,并表明抑制 ZNF148 可能提供一种增强胰岛素分泌的新的治疗策略。